2024 PARTNERS

FibroFind

FibroFind

Expertise Partner

FibroFind is a rapidly developing biomedical sciences company with a deep understanding of fibrosis biology that has employed this knowledge to design bespoke human tissue assays.  Our proprietary bioreactor cultured precision-cut tissue slices (PCTS) offer superior performance for biomarker identification, toxicology, target discovery and drug efficacy evaluation.  Harnessing the power of robotics, AI-guided automated data analysis and a highly skilled technical team, FibroFind delivers unmatched technical quality in studies. Our current portfolio includes healthy and IPF-lung PCTS in 24, and 96 well formats, allowing us to tailor studies to best meet your investigative requirements.

www.fibrofind.com

Biomodels

Biomodels

Exhibition Partner

Biomodels LLC, a preclinical CRO, conducts predictive and translational studies for biotechnology and pharmaceutical companies in the areas of fibrosis, pulmonary and inflammatory diseases, in addition to several other clinical indications. Biomodels specializes in (non-GLP) customized efficacy studies that optimize dose, schedule, and define mechanism of action. Additionally, Biomodels’ state of the art Germ-Free and Gnotobiotic animal facility allows for the analysis of the role of the microbiota both in disease pathogenesis and in therapeutic efficacy.

www.biomodels.com

images

Aragen Life Sciences

Exhibition Partner

ragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. Aragen offers end-to-end integrated or standalone solutions to advance small and large molecule programs from concept to commercialization. Established in 2001, the Company operates through a global network of six sites with a team of 3800+ employees and 450+ PhDs. Its expertise and experience have enabled over 450 customers (including 7 of the top 10 pharma companies globally) in advancing their research programs from early discovery through development and commercialization.

Aragen’s innovative mindset, infrastructure, flexible business models, a clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and
animal health industries globally.

www.aragen.com

NOVALIX, 8th Antifibrotic Drug Development Summit 2024

Novalix

Exhibition Partner

Novalix is an integrated drug discovery CRO supporting therapeutic programs from target identification to the delivery of preclinical candidates. It enables successful discovery programs through an award-winning team of medicinal chemistry and pharmacology scientists, and a variety of screening and characterization technologies, including a DNA-encoded library platform and biophysical techniques.

www.novalix.com

Aptamer Group, 8th Antifibrotic Drug Development Summit 2024

Aptamer Group

Event Partner

Aptamer Group is the developer of custom affinity tools for the life science industry through its proprietary Optimer® platform.

Optimer binders are affinity ligands that can be used as an antibody alternative to offer novel solutions and improvements to current processes across therapeutic, diagnostic, and research sectors. These binders are being applied as direct therapeutics and delivery vehicles for the targeted delivery of oligonucleotide and small molecule therapeutics to specific tissues, along with reagents to hit new targets and challenging tissues.

www.aptamergroup.com

Inoviem

Inoviem

Event Partner

Inoviem Scientific (2011-Strasbourg) allows informed decision-making in drug discovery by providing enabling information that bridges the gap between preclinical and clinical development. With direct patient access, Inoviem collects fresh pathological samples for ex-vivo pharmacology and personalized medicine in fibrotic indications, including IPF, COPD, NASH, and more. Its label-free platforms deliver validated target engagement, MoA deconvolution and patient stratification, unlocking the full potential of drug development programs while accelerating and de-risking pharma and biotech pipelines.

www.inoviem.com